All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

BPX-601 and BPX-603 Trials Discontinued in Advanced Solid Tumors

March 15th 2023

Bellicum Pharmaceuticals has discontinued 2 phase 1/2 trials evaluating the safety and preliminary efficacy of the GoCAR T-cell products BPX-601 and BPX-603 in combination with rimiducid in heavily pretreated patients with advanced solid tumors following an assessment of the risk/benefit profile of the combination of BPX-601 and rimiducid.

NCCN Adds Ripretinib to Guidelines for Second-line Treatment of GIST

March 15th 2023

Ripretinib has been added to the National Comprehensive Cancer Network Guidelines as a preferred regimen in the second-line treatment of patients with gastrointestinal stromal tumor who are intolerant to sunitinib.

Ovarian Cancer Prevention With the Opportunistic Salpingectomy: An Opportunity for Multidisciplinary Collaboration

March 15th 2023

A new understanding of pathogenesis has given rise to a promising prevention strategy for women at an average risk of developing ovarian cancer through surgical removal of the fallopian tubes, referred to as an opportunistic salpingectomy.

Novel Treatments Give Hope for a Transformed Transplant Community

March 15th 2023

Improvements in graft-vs-host disease and transplant-related mortality have created a wave of hope for clinicians treating their patients with hematologic malignancies, stemming from the encouraging data seen with Orca-T and other novel therapeutics in the pipeline.

EP0042 Wins FDA Orphan Drug Status for Acute Myeloid Leukemia

March 14th 2023

The FDA has granted an orphan drug designation to EP0042 for use as a potential therapeutic option in patients with acute myeloid leukemia with acquired resistance to FLT3 inhibitors.

Vorasidenib Meets PFS End Point in IDH1/2-Mutant Low-Grade Glioma

March 14th 2023

Vorasidenib monotherapy elicited a statistically significant and clinically meaningful improvement in progression-free survival compared with placebo in patients with residual or recurrent IDH1/2-mutant low-grade glioma.

China ARCHES Study Meets Primary, Secondary End Points in Metastatic Prostate Cancer

March 14th 2023

Enzalutamide plus androgen deprivation therapy produced a statistically significant improvement in time to prostate-specific antigen progression compared with ADT and placebo in men with metastatic hormone-sensitive prostate cancer, meeting the primary end point of the phase 3 China ARCHES study.

Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors

March 14th 2023

Although the immune system plays a vital role in attacking tumor cells, the immune mechanisms vary from tumor to tumor, and factors in the tumor microenvironment can reduce the effectiveness of the body’s immune response.

Real-World Research Highlights the Importance of Targeted NSCLC Treatment

March 14th 2023

Daryl Pritchard, PhD, discussed how recent findings highlight the importance of targeted therapy in advanced lung cancer, areas where the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology could be updated to better encapsulate real-world practice patterns, and the ways in which increased access to molecular testing can help usher in a new era of personalized medicine.

Gifts from Walther, Regenstrief Foundations Create Cancer Informatics Chair at IU Simon Comprehensive Cancer Center

March 14th 2023

Gifts totaling $3 million will create an endowed chair in cancer informatics at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

Adjuvant Targeted Therapies Could Continue to Shift the Treatment Paradigm in NSCLC

March 14th 2023

Adjuvant osimertinib and other targeted therapies, such as KRAS G12C inhibitors, could continue to change the perioperative treatment landscape in non–small cell lung cancer.

Utilizing PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer in a Tailored Fashion

March 14th 2023

Precision medicine and personalized medicine are 2 concepts that have pushed their way to the forefront of oncology practice.

Navigating Systemic Therapy for RCC: Balancing Risk Status and Response

March 13th 2023

Despite a perhaps overwhelming number of combination regimens available for use in the frontline setting for patients with renal cell carcinoma, treatment decisions can still largely boil down to a patient’s risk status. For second-line therapy, investigators are looking to contemporary trials for guidance.

FDA Approves Nelarabine Injection for T-cell Leukemia and Lymphoma

March 13th 2023

The FDA has approved nelarabine for injection for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, according to an announcement from Shorla Oncology.

FDA Places Clinical Hold on Phase 1 Trial of XMT-2056 in HER2-expressing Solid Tumors

March 13th 2023

The FDA has placed a clinical hold on a phase 1 trial investigating the antibody-drug conjugate XMT-2056 for the treatment of patients with advanced/recurrent solid tumors that express HER2.

Survey Reveals Importance of Precise PV Treatment Guidelines and Research

March 13th 2023

Heterogeneous patterns of polycythemia vera management indicate the need for continued research in this disease and increased guideline specificity across treatment centers in Italy.

Florida Cancer Specialists & Research Institute a Top Performer in the Center for Medicare & Medicaid Innovation’s Oncology Care Model

March 13th 2023

Florida Cancer Specialists & Research Institute, LLC, a consistent top performer among the 126 U.S.-based oncology practices that participated in the Center for Medicare & Medicaid Innovation Oncology Care Model, shares its results in the payment and delivery model’s final wave which ended in June 2022 in a newly released case study.

FDA Receives Type A Meeting Request for Synthetic Hypericin in Early-stage Cutaneous T-cell Lymphoma

March 13th 2023

Soligenix has submitted a Type A meeting request to the FDA to discuss the contents of a refusal to file letter from the regulatory agency regarding the new drug application for synthetic hypericin for the treatment of early-stage cutaneous T-cell lymphoma.

Media Training Helps Investigators, Institutions Shine

March 13th 2023

Here are 5 tips and tricks to help you shine when the spotlight is on you.

AB011 Plus CAPOX Demonstrates Preliminary Safety, Efficacy in Advanced Gastric/GEJ Cancer

March 13th 2023

The combination of AB011 and capecitabine/oxaliplatin was found to have a manageable safety profile and to showcase early clinical benefit when used as first-line treatment in patients with gastric cancer or gastroesophageal junction adenocarcinoma.